- Home
- AMBO vs BTAI Comparison
AMBO vs BTAI Comparison
Compare AMBO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- BTAI
- Stock Information
- Founded
- AMBO 2000
- BTAI 2017
- Country
- AMBO United States
- BTAI United States
- Employees
- AMBO N/A
- BTAI N/A
- Industry
- AMBO Other Consumer Services
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- BTAI Health Care
- Exchange
- AMBO Nasdaq
- BTAI Nasdaq
- Market Cap
- AMBO 7.1M
- BTAI 7.2M
- IPO Year
- AMBO 2010
- BTAI 2018
- Fundamental
- Price
- AMBO $2.48
- BTAI $1.81
- Analyst Decision
- AMBO
- BTAI Buy
- Analyst Count
- AMBO 0
- BTAI 5
- Target Price
- AMBO N/A
- BTAI $42.60
- AVG Volume (30 Days)
- AMBO 20.9K
- BTAI 1.2M
- Earning Date
- AMBO 12-30-2024
- BTAI 03-27-2025
- Dividend Yield
- AMBO N/A
- BTAI N/A
- EPS Growth
- AMBO N/A
- BTAI N/A
- EPS
- AMBO 0.11
- BTAI N/A
- Revenue
- AMBO $9,392,000.00
- BTAI $2,266,000.00
- Revenue This Year
- AMBO N/A
- BTAI $105.36
- Revenue Next Year
- AMBO N/A
- BTAI $46.93
- P/E Ratio
- AMBO $23.61
- BTAI N/A
- Revenue Growth
- AMBO 2.50
- BTAI 64.20
- 52 Week Low
- AMBO $1.00
- BTAI $1.72
- 52 Week High
- AMBO $5.55
- BTAI $49.58
- Technical
- Relative Strength Index (RSI)
- AMBO 47.68
- BTAI 37.89
- Support Level
- AMBO $2.43
- BTAI $1.76
- Resistance Level
- AMBO $3.20
- BTAI $2.11
- Average True Range (ATR)
- AMBO 0.35
- BTAI 0.26
- MACD
- AMBO -0.05
- BTAI 0.01
- Stochastic Oscillator
- AMBO 12.96
- BTAI 7.33
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.